Everything below concerns WADA. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-02. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
In lichenology, where many genera are small (the average genus has approximately 19 species, and a quarter of genera are monospecific), changes at genus level can particularly cause fragmentation. Discussions continue on how best to balance the need for monophyletic groups with the practical need for taxa that are reasonably diagnosable and useful. Nimis's five‑point checklist, although written for generic splits, provided an early blueprint for balancing lineage evidence with the practical need for taxonomic stability. Emerging technologies offer new tools for lichen systematics. Long-read sequencing is making it feasible to assemble complete genomes of lichen fungi and their photobionts, providing extensive character data and resolving complex structural variants. Environmental metagenomics can detect lichen DNA in soil and air samples, potentially allowing surveys of overlooked microlichen diversity. Machine learning models show promise for identifying lichens from photographs and detecting patterns in multidimensional datasets. However, these technologies require robust reference databases and high-quality baseline taxonomy to be effective. As Lücking (2020) notes, incomplete or flawed taxonomy will simply be perpetuated more rapidly by automated systems. The principle of the "minimum adequate method" remains relevant—traditional methods like culture experiments and careful morphological observation continue to answer questions that sequencing alone cannot.
The Hmd holoenzyme includes the protein homodimer as well as its associated iron-containing cofactor. Several species of methanogens have been characterized that express enzymes in the Hmd hydrogenase family. Between species the enzyme is found with differing numbers of sub-units and some minor amino acid sequence variations. The monomer is approximately 45,000 Da in mass, although this value varies from species to species. The enzymatic activity of the enzyme is lost upon exposure to sunlight or UV. Photolysis causes the release of an iron atom and two molecules of carbon monoxide. In the holoenzyme the Fe and CO molecules are found associated with a 542 Da cofactor.
Linked-read sequencing, a type of DNA sequencing technology, uses specialized technique that tags DNA molecules with unique barcodes before fragmenting them. Unlike traditional sequencing technology, where DNA is broken into small fragments and then sequenced individually, resulting in short read lengths that has difficulties in accurately reconstructing the original DNA sequence, the unique barcodes of linked-read sequencing allows scientists to link together DNA fragments that come from the same DNA molecule. A pivotal benefit of this technology lies in the small quantities of DNA required for large genome information output, effectively combining the advantages of long-read and short-read technologies.
Sources: en.wikipedia.org
Internationally, the company often pairs with other parties to operate locations, or it will outright sell the operational and administrative rights to a franchisee which is given the designation of master franchise for the territory. The master franchise will then be expected to sub-license new stores, provide training support, and ensure operational standards are maintained. In exchange for the oversight responsibilities, the master franchise will receive administrative and advertising support from Burger King Corporation to ensure a common marketing scheme. The 3G Capital ownership group announced in April 2011 that it would begin divesting itself of many corporate owned locations with the intent to increase the number of privately held restaurants to 95%. In 2016, the percentage of privately owned Burger King establishments grew to 99.5%. RBI maintains that approximately 100% of Burger King franchises are privately held restaurants.
=== Other signs and symptoms === People with fibromyalgia may experience hyperalgesia (abnormally increased sensitivity to pain) and allodynia (pain from a stimulus that does not normally elicit pain). People with FM may be intolerant to bright lights, loud noises, perfumes, and cold. Other symptoms may be musculoskeletal stiffness, environmental sensitivity, hypervigilance, sexual dysfunction, and visual symptoms. Nocturnal myoclonus can be present in people with fibromyalgia. A 2021 review found that fibromyalgia can also cause ocular discomfort (foreign body sensation and irritation) and visual disturbances (blurred vision).
== Dietary sources of energy == The typical human diet consists chiefly of carbohydrates, fats, proteins, water, ethanol, and indigestible components such as bones, seeds, and fibre (mostly cellulose). Carbohydrates, fats, and proteins typically comprise ninety percent of the dry weight of food. Ruminants can extract food energy from the respiration of cellulose because of bacteria in their rumens that decompose it into digestible carbohydrates. Other minor components of the human diet that contribute to its energy content are organic acids such as citric and tartaric, and polyols such as glycerol, xylitol, inositol, and sorbitol. Some nutrients have regulatory roles affected by cell signaling, in addition to providing energy for the body. For example, leucine plays an important role in the regulation of protein metabolism and suppresses an individual's appetite. Small amounts of essential fatty acids, constituents of some fats that cannot be synthesized by the human body, are used (and necessary) for other biochemical processes. The approximate food energy contents of various human diet components, to be used in package labeling according to the EU regulations and UK regulations, are:
Sources: en.wikipedia.org
==== Canada ==== Semaglutide's pharmaceutical data exclusivity period expired in Canada in January 2026. Novo Nordisk failed to pay a required patent maintenance fee, and their patent on the chemical structure of the drug expired in 2020. Several applications and approvals for generic semaglutide followed, both for type 2 diabetes and weight loss. In April 2026, Dr. Reddy's Laboratories received approval to sell generic semaglutide in injectable format in Canada, having applied in February 2024. Later that week, Apotex's generic semaglutide (Apo-Semaglutide) was also approved as an injectable drug. In June 2026, Health Canada approved Sevmia, Apotex's injectable generic semaglutide for weight management in people aged 12 years and above. In July 2026, Aspen Pharmacare received approval for a generic injectable form of the drug for diabetes (Aspen-Semaglutide). Several other applications to sell generic versions have been made, but not yet approved, including by Sandoz, Taro Pharmaceuticals and Teva Pharmaceuticals. Hims & Hers Health expects to partner with an approved manufacturer to market a generic version. Sandoz' 2026 offering would be for diabetes only, while Biocon hopes to offer generic semaglutide for diabetes and weight loss by 2027. Novo Nordisk is considering competing against the new generic drugs with Plosbrio and Poviztra: additional brand names for semaglutide, but marketed at a lower price than Ozempic and Wegovy.
In this model the racemic state is unstable in the sense that the slightest enantiomeric excess will be amplified to a completely homochiral state. This can be shown by computing the reaction rates from the law of mass action:
== Illicit production == Illicit production and sale of etonitazene has been limited. Identified on the Moscow illegal drug market in 1998, it was primarily smoked in laced cigarettes. A chemist at Morton Thiokol synthesized the compound for his own use. The drug was produced in Russia in 1996 and sold as 'Chinese Dwarf'. The drug resulted in an unconfirmed number of deaths due to its uncertain potency. Etonitazene appears to have a steep dose-response curve, and unpredictable pharmacokinetics especially when injected, in a similar manner to some other potent opioids such as dextromoramide, which may cause etonitazene to be especially hazardous when compared to opioids of similar potency such as fentanyl.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.